Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATGC-100 vs Botox for Glabellar Lines
NCT03970876Phase 2Completed
- Sponsor
- EuBiologics
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of ATGC-100 in glabellar lines, sponsored by EuBiologics. Started Apr 2019; status: completed.
02
Drugs
ATGC-100
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03970876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970876.